

AD_____

Award Number: DAMD17-03-1-0630

TITLE: Targeted Killing of Breast Tumor Stem Cells

PRINCIPAL INVESTIGATOR: Si-Yi Chen, Ph.D.

CONTRACTING ORGANIZATION: Baylor College of Medicine
Houston, Texas 77030-3498

REPORT DATE: September 2004

TYPE OF REPORT: Annual

20060213 024

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE September 2004	3. REPORT TYPE AND DATES COVERED Annual (15 Aug 2003 - 14 Aug 2004)	
4. TITLE AND SUBTITLE Targeted Killing of Breast Tumor Stem Cells			5. FUNDING NUMBERS DAMD17-03-1-0630	
6. AUTHOR(S) Si-Yi Chen, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Baylor College of Medicine Houston, Texas 77030-3498 <i>E-Mail:</i> bcochran@bcm.tmc.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 Words) It has been postulated that the heterogeneous, metastatic breast cancer cells are originated from a single or a small number of distinct tumor stem cells, and that only the cancer stem cells have the unlimited ability to proliferate and metastasize to different tissues and organs. A recent study found that the CD44+/CD24- breast tumor cells may be breast tumor stem cells. CD44 is a receptor that binds to hyaluronan (HA), a carbohydrate consisting of β 1,3 N-acetyl glucosaminyl- β 1,4 glucuronide. We have proposed to generate CD44-targeted liposome to selectively destroy the CD44+ breast tumor cells. Toward the goal, we have prepared HA molecules from human umbilical cord hyaluronic acid by hydrolysed by Bee venom. However, we have encountered the technical difficulty to produce CD44-targeted liposomes that are incorporated with HA molecules. Due to the technical problems, this proposed study has been extended for additional one year.				
14. SUBJECT TERMS No subject terms provided.			15. NUMBER OF PAGES 5	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	
Reportable Outcomes.....	
Conclusions.....	
References.....	
Appendices.....	

USAMRMC FY02 BREAST CANCER RESEARCH PROGRAM

Grant/Contract/MIPR No.: DAMD17-03-1-0630

Principal Investigator: Si-Yi Chen, Ph.D.

Institution: Baylor College of Medicine
Houston, Texas 77030

Report Title: Targeting Killing of Breast Tumor Stem Cells

Report Type: Annual (First)

Award Mechanism: Concept

Date of Report: September 2004

Reporting Period: 15 August 2003 – 14 August 2004

Introduction.....4

It has been postulated that the heterogeneous, metastatic breast cancer cells are originated from a single or a small number of distinct tumor stem cells, and that only the cancer stem cells have the unlimited ability to proliferate and metastasize to different tissues and organs. Such a breast tumor stem cell population was recently identified (1). It was found that only one cell type with high levels of CD44 and low levels of CD24, about 1% to 15%, of breast cancer cells removed from patients were capable of forming new malignant tumors in the nude mice (mammary glands). As few as 100 to 200 of these CD44+/CD24- breast tumor cells readily formed tumors in mice, while tens of thousands of other tumor cells from the same tumor failed to grow, suggesting that the CD44+/CD24- breast tumor cells may be breast tumor stem cells (1). CD44 is a receptor that binds to hyaluronan (HA), a carbohydrate consisting of β 1,3 N-acetyl glucosaminyl- β 1,4 glucuronide (2). CD44 is found at low levels on a number of cell types in normal tissues, including epithelial, hemopoietic, and neuronal cells. However, these normal cells are either not in direct contact with the blood or require activation before they bind to HA (2). Thus, CD44 may be a suitable surface marker for targeted killing of breast tumor stem cells that express a high level of this molecule.

Body.....4

The goal of this study is to generate CD44-targeted liposome to selectively destroy the CD44+ breast tumor cells.

Task 1. To generate and characterize CD44-targeted liposome that is incorporated with HA. We have prepared HA molecules from human umbilical cord hyaluronic acid by hydrolysed by Bee venom. Hyaluronic acid fragments were separated on 11 x 265 mm column of the formate form of Bio-Rad AG-3 x 4A ion-exchange resin. However, we have encountered the technical difficulty to produce CD44-targeted liposomes that are incorporated with HA molecules. Due to the technical problems, this proposed study has been extended for additional one year.

We are using the method described by Szoka's laboratory (*Cancer Research* 61, 2592-2601, 2001) to prepare HA-incorporated liposome. Briefly, Chol (Sigma Co. (St. Louis)) was recrystallized from methanol. Lipid films were prepared by drying 10 μ mol of lipid including POPE-HA or DPPE-HA from solvent (butanol saturated with distilled water or chloroform:methanol 7:3, respectively) under vacuum using rotary evaporator at room temperature. Liposomes (composed of POPC:Chol:HA-POPE 60:40:3) were prepared by rehydrating the lipid film with 1 ml of 10 mM HEPES, 5% glucose (pH 7.4), followed by mixing on a vortex mixer for 1 min, sonication for 15 min in a bath type sonicator (Laboratory Supplies Company Inc., Hicksville, NY).

The problem we encountered is that the sizes of HA-liposomes we generated were mostly larger than 0.5 μ m, which was determined by light scattering analyses (N4 particle size analyzer, Coulter). The sizes of HA-liposomes are too big to be biologically active (should be in the range of 0.1-0.2 μ m). Currently, we are modifying the protocol by testing different experimental conditions in order to achieve a smaller size of liposomes.

Task 2. To evaluate if HA-targeted liposomes (HALs) can selectively bind to the breast cancer cells expressing high levels of CD44.

To be performed

Task 3. To evaluate if HA-targeted, drug-containing liposomes (HALs) can selectively kill the breast cancer cells expressing high levels of CD44.

To be performed

Key Research Accomplishments.....4

Experiments are under way to accomplish the Task 1.

Reportable Outcomes.....4

Experiments are under way to accomplish the Task 1.

Conclusions.....4

Experiments are under way to accomplish the Task 1.